+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Middle East & Africa Mid-Size Pharmaceutical Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Drug Development Type, Formulation, and Therapy Class

  • PDF Icon

    Report

  • 128 Pages
  • September 2022
  • Region: Africa, Middle East
  • The Insight Partners
  • ID: 5668317
UP TO OFF until Dec 31st 2024
The mid-size pharmaceutical market in the Middle East & Africa is expected to grow from US$ 19,569.41 million in 2022 to US$ 23,913.96 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.

Pharmaceutical companies are interested in ensuring R&D achieves their intended goal. The number of new drugs approved each year has also increased over the last decade. Efforts are being made to achieve greater effectiveness and efficiency in meeting patients' needs. Recent studies have estimated average R&D costs per new drug are less than US$ 1 billion to over US$ 2 billion per drug. These estimates include the cost of laboratory and clinical trials of successful new drugs and drugs that enter clinical trials but fail or do not go through the laboratory development phase. These top trends transform the pharmaceutical industry and can have short-term and long-term implications. Therefore, the surging focus on R&D drives the growth of the Middle East & Africa mid-size pharmaceutical market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Middle East & Africa mid-size pharmaceutical market. The Middle East & Africa mid-size pharmaceutical market is expected to grow at a good CAGR during the forecast period.

Middle East & Africa Mid-Size Pharmaceutical Market Segmentation

The Middle East & Africa mid-size pharmaceutical market is segmented on the basis of type, drug development type, formulation, therapy class, and country.
  • Based on type, the Middle East & Africa mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share.
  • Based on drug development type, the market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022.
  • Based on formulation, the Middle east & Africa mid-size pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022.
  • Based on therapy class, the market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022.
  • Based on country, the Middle East & Africa mid-size pharmaceutical market is segmented into Saudi Arabia, South Africa, the UAE, and Rest of Middle East & Africa. Saudi Arabia held the largest market share in 2022.
Alexion Pharmaceuticals, Inc.; Bausch Health Companies Inc.; Daiichi Sankyo Company Limited; Endo Pharmaceuticals Inc.; Mallinckrodt; and Sun Pharmaceutical Industries Ltd are among the leading companies operating in the mid-size pharmaceutical market in the region.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Mid-Size Pharmaceutical - By Type
1.3.2 MEA Mid-Size Pharmaceutical - By Drug Development Type
1.3.3 MEA Mid-Size Pharmaceutical - By Formulation
1.3.4 MEA Mid-Size Pharmaceutical - By Therapy Area
1.3.5 MEA Mid-Size Pharmaceutical - By Country
2. Mid-Size Pharmaceutical- Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Mid-Size Pharmaceutical - Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Expert Opinion
5. Mid-Size Pharmaceutical Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Cases of Chronic Disorders
5.1.2 New Product Approval and Launches
5.2 Market Restraints
5.2.1 High Competition Among Market Players
5.3 Market Opportunities
5.3.1 Rising Number of Healthcare Start-ups
5.4 Future Trends
5.4.1 Surging Focus on R&D
5.5 Impact Analysis
6. Mid-Size Pharmaceutical Market- MEA Analysis
6.1 MEA Mid-Size Pharmaceutical Market Revenue Forecast And Analysis
7. MEA Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028- by Type
7.1 Overview
7.2 MEA Mid-Size Pharmaceutical Market Revenue Share, by Type (2022 and 2028)
7.3 Prescription
7.3.1 Overview
7.3.2 Prescription: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Over-the-Counter (OTC)
7.4.1 Overview
7.4.2 Over-the-Counter: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
8. MEA Mid-Size Pharmaceutical Market Analysis - By Drug Development Type
8.1 Overview
8.2 MEA Mid-Size Pharmaceutical Market Revenue Share, by Drug Development Type (2022 and 2028)
8.3 In-House
8.3.1 Overview
8.3.2 In-House: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Outsource
8.4.1 Overview
8.4.2 Outsource: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
9. MEA Mid-Size Pharmaceutical Market - By Formulation
9.1 Overview
9.2 MEA Mid-Size Pharmaceutical Market, by Formulation, 2022 and 2028 (%)
9.3 Tablets and Capsules
9.3.1 Overview
9.3.2 Tablets and Capsules: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
9.4 Injectables
9.4.1 Overview
9.4.2 Injectables: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
9.5 Sprays
9.5.1 Overview
9.5.2 Sprays: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
9.6 Other Formulations
9.6.1 Overview
9.6.2 Others: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
10. MEA Mid-Size Pharmaceutical Market - By Therapy Class
10.1 Overview
10.2 MEA Mid-Size Pharmaceutical Market, by Therapy Class, 2022 and 2028 (%)
10.3 Cardiovascular Diseases
10.3.1 Overview
10.3.2 Cardiovascular Diseases: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Pain Management
10.4.1 Overview
10.4.2 Pain Management: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
10.5 Diabetes
10.5.1 Overview
10.5.2 Diabetes: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
10.6 Cancer
10.6.1 Overview
10.6.2 Cancer: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
10.7 Other Diseases
10.7.1 Overview
10.7.2 Other Diseases: Mid-Size Pharmaceutical Market - Revenue and Forecast to 2028 (US$ Million)
11. MEA Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 - Country Analysis
11.1 Overview
11.1.1 MEA Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Country (%)
11.1.1.1 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.1.3 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
11.1.1.1.4 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)
11.1.1.1.5 UAE: Mid-Size Pharmaceutical Market, by Formulation - Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.6 UAE: Mid-Size Pharmaceutical Market, by Therapy Area - Revenue and Forecast to 2028 (US$ Million)
11.1.1.2 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.2.3 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
11.1.1.2.4 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)
11.1.1.2.5 Saudi Arabia: Mid-Size Pharmaceutical Market, by Formulation - Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.6 Saudi Arabia: Mid-Size Pharmaceutical Market, by Therapy Area - Revenue and Forecast to 2028 (US$ Million)
11.1.1.3 South Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 South Africa Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.3.3 South Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
11.1.1.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)
11.1.1.3.5 South Africa: Mid-Size Pharmaceutical Market, by Formulation - Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.6 South Africa: Mid-Size Pharmaceutical Market, by Therapy Area - Revenue and Forecast to 2028 (US$ Million)
11.1.1.4 Rest of MEA: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.4.1 Overview
11.1.1.4.2 Rest of MEA: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.4.3 Rest of MEA: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)
11.1.1.4.4 Rest of MEA: Metabolomics Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)
11.1.1.4.5 Rest of MEA: Mid-Size Pharmaceutical Market, by Formulation - Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.6 Rest of MEA: Mid-Size Pharmaceutical Market, by Formulation - Revenue and Forecast to 2028 (US$ Million)
12. Mid-Size Pharmaceutical Market-Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 DAIICHI SANKYO COMPANY LIMITED
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Bausch Health Companies Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Sun Pharmaceutical Industries Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Alexion Pharmaceuticals, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Mallinckrodt
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Endo Pharmaceuticals Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

Companies Mentioned

  • Alexion Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.
  • Daiichi Sankyo Company Limited
  • Endo Pharmaceuticals Inc.
  • Mallinckrodt
  • ssSun Pharmaceutical Industries Ltd

Table Information